News and publications

EP Solutions SA is the sponsor of the MAP-CRT multicentre clinical trial. This study is designed to assess whether an ECGi measurement with Amycard 01C can be used to predict the outcome of cardiac resynchronization therapy.

Despite the added difficulties due to the covid-19 pandemic, five sites are live:

• Hospital da Luz in Lisbon,
• Petrovsky Institute in Moscow,
• Vishnevsky Institute in Moscow,
• Centro Cardiologico Monzino in Milan,
• and Mannheim University.

Results are expected later this year.